Cervical cancer is the leading cause of cancer death globally among women. The American Cancer Society estimated that about 14,100 new cases of invasive cervical cancer will be diagnosed in the United States by 2022. Fortunately, cervical cancer can often be found early, and sometimes even prevented, by having regular screening tests. If detected early, cervical cancer is one of the most successfully treatable cancers.
Incidence rates of cervical cancer dropped by more than 50% from the mid-1970s to the mid-2000s due in part to an increase in early screening, which can find cervical changes before they turn cancerous. It’s supported by a broad range of data: When detected at an early stage, the 5-year survival rate for people with invasive cervical cancer is 92%. If cervical cancer has spread to surrounding tissues or organs and/or the regional lymph nodes, the rate is 58%, and it is as low as 17% if cancer has spread to a distant part of the body.
Screening aims to detect precancerous lesions, that is, abnormalities in the cells of the cervix, which, if left untreated, can develop into cervical cancer. Screening and treatment of precancerous lesions also referred to as “secondary prevention” is the second pillar of the recommended WHO’s comprehensive approach to cervical cancer.
WHO proposed a global strategy to accelerate the elimination of cervical cancer as a public health problem, and it recommended that 70% of women are screened with high-performance tests by ages 35 and 45 years. HPV vaccination (primary prevention) and cervical cancer screening, with the treatment of precancerous lesions, must be scaled up together in low- and middle-income countries.
Colposcope plays an important role in cervical cancer screening.
Different from traditional optical colposcope, video colposcope displays the captured images on a viewing monitor. High-resolution cameras ensure superior image quality to reproduce the examination area to the greatest extent.
R-wayTM Evaluation Program is built to help gynecologists easily locate CIN2+ lesions, providing technical assurance for decreasing the morbidity and mortality of cervical cancer. Learn more about EDAN R-way system: https://www.edan.com/news/company104/97.html.
For more information about EDAN Video Colposcope, please visit https://www.edan.com/product/m/OBGYN_C6HD_C6AHD2.html.
